ID   IGR-39
AC   CVCL_2076
SY   IGR 39; IGR39; PM1; Institut Gustave Roussy-39
DR   CLO; CLO_0006671
DR   CLDB; cl2626
DR   BioGRID_ORCS_Cell_line; 638
DR   BioSample; SAMN10988096
DR   cancercelllines; CVCL_2076
DR   Cell_Model_Passport; SIDM01065
DR   Cosmic; 886828
DR   Cosmic; 2163786
DR   DepMap; ACH-000550
DR   DSMZ; ACC-239
DR   DSMZCellDive; ACC-239
DR   ESTDAB; ESTDAB-037
DR   GEO; GSM557940
DR   GEO; GSM557942
DR   GEO; GSM887159
DR   GEO; GSM888231
DR   GEO; GSM1669929
DR   IARC_TP53; 30078
DR   LINCS_LDP; LCL-1249
DR   PharmacoDB; IGR39_653_2019
DR   Progenetix; CVCL_2076
DR   Wikidata; Q54897368
RX   PubMed=405430;
RX   PubMed=2337917;
RX   PubMed=2344628;
RX   PubMed=6539703;
RX   PubMed=6929009;
RX   PubMed=11668190;
RX   PubMed=15592718;
RX   PubMed=21584902;
RX   PubMed=22460905;
RX   PubMed=23851445;
RX   PubMed=25984343;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 34 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-239).
CC   HLA typing: B*39:01:01,39:01:01; C*07:02,07:02; DPB1*31:01,09:01; DQB1*06:02; DRB1*16:02 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Homozygous (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23851445; DepMap=ACH-000550).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys229Tyrfs*10 (c.686_687delGT); ClinVar=VCV000863486; Zygosity=Unspecified (DepMap=ACH-000550).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; shRNA library screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=1.8%; Native American=1.18%; East Asian, North=2.76%; East Asian, South=0%; South Asian=0%; European, North=58.99%; European, South=35.28% (PubMed=30894373).
CC   Discontinued: ESTDAB; ESTDAB-037; probable.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): DSMZ=ACC-239
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 15
ST   D19S433: 13
ST   D21S11: 31.2,32.2
ST   D2S1338: 19,24
ST   D3S1358: 17,18
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 14,15
ST   FGA: 22
ST   Penta D: 9
ST   Penta E: 12,16
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17,21
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2075 ! IGR-37
SX   Male
AG   26Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 37
//
RX   PubMed=405430; DOI=10.1111/1523-1747.ep12496554;
RA   Foa C., Aubert C.;
RT   "Cellular localization of tyrosinase in human malignant melanoma cell
RT   lines.";
RL   J. Invest. Dermatol. 68:369-378(1977).
//
RX   PubMed=2337917;
RA   Aquaron R., Dutoit C., Reynier M., Aubert C.;
RT   "Calmodulin content and distribution in six human melanoma cell
RT   lines.";
RL   Cell. Mol. Biol. 36:85-92(1990).
//
RX   PubMed=2344628; DOI=10.1016/S0309-1651(05)80010-4;
RA   Aubery M., Reynier M., Lopez M., Ogier-Denis E., Font J., Bardin F.;
RT   "WGA binding to the surface of two autologous human melanoma cell
RT   lines: different expression of sialyl and N-acetylglucosaminyl
RT   residues.";
RL   Cell Biol. Int. Rep. 14:275-286(1990).
//
RX   PubMed=6539703; DOI=10.1016/0277-5379(84)90015-4;
RA   Weinreb A., Travo P.;
RT   "Discrimination between human melanoma cell lines by fluorescence
RT   anisotropy.";
RL   Eur. J. Cancer Clin. Oncol. 20:673-677(1984).
//
RX   PubMed=6929009; DOI=10.1093/jnci/64.5.1029;
RA   Aubert C., Rouge F., Galindo J.-R.;
RT   "Tumorigenicity of human malignant melanocytes in nude mice in
RT   relation to their differentiation in vitro.";
RL   J. Natl. Cancer Inst. 64:1029-1040(1980).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=21584902; DOI=10.1002/gcc.20890;
RA   Swoboda A., Rasin-Streden D., Schanab O., Okamoto I., Pehamberger H.,
RA   Petzelbauer P., Mikula M.;
RT   "Identification of genetic disparity between primary and metastatic
RT   melanoma in human patients.";
RL   Genes Chromosomes Cancer 50:680-688(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035.1-140035.12(2014).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//